Page 252 - 2021_03-Haematologica-web

898
Letters to the Editor
VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) | AbbVie News Center [Internet]. [cited 2020 Mar 30];Available from: https://news.abbvie.com/news/press-releases/abbvie-announces- positive-topline-results-from-phase-3-trial-venclexta-venetoclax-in- combination-with-azacitidine-in-patients-with-acute-myeloid- leukemia-aml.htm
7. A new standard emerges: rational use of venetoclax to inhibit BCL- 2 Allows Treatment of AML In Older Patients [Internet]. 2019 [cited 2020 Jan 20];Available from: /Thehematologist/Diffusion/9382.aspx
8. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an internation- al expert panel. Blood 2017;129:424-447.
9. Nanah R, McCullough K, Hogan W, et al. Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: single institution experience. Am J Hematol. 2017;92(9):866-871.
10. Maiti A, Rausch CR, Cortes JE, et al. Outcomes in molecular sub- groups and resistance patterns with ten-day decitabine and veneto- clax (DEC10-VEN) in acute myeloid leukemia. Blood. 2019; 134(Suppl 1):645.
11. Maiti A, DiNardo CD, Ravandi F, et al. Venetoclax, FLT3 inhibitor and decitabine in FLT3mut acute myeloid leukemia: subgroup analysis of a Phase II Trial. Blood 2020;138:1945.
12. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological cor- relates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016; 6(10):1106-1117.
13. Niu X, Zhao J, Ma J, et al. Binding of released Bim to Mcl-1 is a mechanism ofintrinsic resistance to ABT-199 which can be over- come by combination with daunorubicin or cytarabine in AML Cells. Clin Cancer Res. 2016;22(17):4440-4451.
14. Nechiporuk T, Kurtz SE, Nikolova O, et al. The TP53 apoptotic net- work is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019;9(7):910-925.
15. DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combina- tions in older patients with AML. Blood. 2020;135(11):791-803.
16. Taylor J, Lee SC. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies. Genes Chromosomes Cancer. 2019;58(12):889-902.
17. Braun T, Gardin C. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML). Expert Opin Investig Drugs. 2017;26(7):803-811.
18. Bushweller JH. Targeting transcription factors in cancer — from undruggable to reality. Nat Rev Cancer. 2019;19(11):611-624.
19. Zhang Q, Pan R, Han L, et al. Mechanisms of acquired resistance to venetoclax in preclinical AML models. Blood. 2015;126(23):328-328.
haematologica | 2021; 106(3)